Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab.

Caso F, Iaccarino L, Bettio S, Ometto F, Costa L, Punzi L, Doria A.

Immunol Res. 2013 Jul;56(2-3):390-7. doi: 10.1007/s12026-013-8411-1. Review.

PMID:
23572430
2.

Tocilizumab in severe and refractory Behcet's disease: Four cases and literature review.

Deroux A, Chiquet C, Bouillet L.

Semin Arthritis Rheum. 2016 Jun;45(6):733-7. doi: 10.1016/j.semarthrit.2015.11.012. Epub 2015 Dec 2. Review.

PMID:
26743073
3.

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Hirano T, Ohguro N, Hohki S, Hagihara K, Shima Y, Narazaki M, Ogata A, Yoshizaki K, Kumanogoh A, Kishimoto T, Tanaka T.

Mod Rheumatol. 2012 Apr;22(2):298-302. doi: 10.1007/s10165-011-0497-5. Epub 2011 Jul 12.

PMID:
21748365
4.

Therapeutic uses of anti-interleukin-6 receptor antibody.

Kang S, Tanaka T, Kishimoto T.

Int Immunol. 2015 Jan;27(1):21-9. doi: 10.1093/intimm/dxu081. Epub 2014 Aug 20. Review.

PMID:
25142313
5.

Refractory neuro-Behçet treated by tocilizumab: a case report.

Urbaniak P, Hasler P, Kretzschmar S.

Clin Exp Rheumatol. 2012 May-Jun;30(3 Suppl 72):S73-5. Epub 2012 Sep 27.

PMID:
23020826
6.

Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.

Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S, Gentileschi S, Bacherini D, Franceschini R, Frediani B, Galeazzi M, Iannone F, Tosi GM, Cantarini L.

Clin Rheumatol. 2017 Jan;36(1):191-197. doi: 10.1007/s10067-016-3506-4. Epub 2016 Dec 16.

PMID:
27981463
7.

Current and future treatments for Behçet's uveitis: road to remission.

Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Dick AD, Adán A.

Int Ophthalmol. 2014 Apr;34(2):365-81. doi: 10.1007/s10792-013-9788-5. Epub 2013 Jun 1. Review.

PMID:
23729309
8.

Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature.

Soysal T, Salihoğlu A, Esatoğlu SN, Gültürk E, Eşkazan AE, Hatemi G, Hatemi I, Öngören Aydın Ş, Erzin YZ, Başlar Z, Tüzüner N, Ferhanoğlu B, Çelik AF.

Rheumatology (Oxford). 2014 Jun;53(6):1136-41. doi: 10.1093/rheumatology/ket479. Epub 2014 Feb 6. Review.

PMID:
24505123
9.

Refractory pseudoseptic arthritis in Behçet's disease successfully treated with infliximab: a case report and literature review.

Sifuentes Giraldo WA, Guillén Astete CA, Murillo Romero C, Amil Casas I, Rodríguez García AM, Bachiller Corral FJ.

Mod Rheumatol. 2014 Jan;24(1):199-205. doi: 10.3109/14397595.2013.852839. Review.

PMID:
24261779
10.

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.

Olivieri I, Leccese P, D'Angelo S, Padula A, Nigro A, Palazzi C, Coniglio G, Latanza L.

Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S54-7. Epub 2011 Sep 27.

PMID:
21968237
11.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
12.

Tocilizumab in refractory aortitis: study on 16 patients and literature review.

Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, Mata C, Melchor S, Aurrecoechea E, Calvo-Alén J, Lluch P, Moll C, Mínguez M, Herrero-Beaumont G, Bravo B, Rubio E, Freire M, Peiró E, González-Vela C, Rueda-Gotor J, Pina T, Palmou-Fontana N, Calvo-Río V, Ortiz-Sanjuán F, González-Gay MÁ.

Clin Exp Rheumatol. 2014 May-Jun;32(3 Suppl 82):S79-89. Epub 2014 May 15.

PMID:
24854377
13.

Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis.

Makol A, Gibson LE, Michet CJ.

J Clin Rheumatol. 2012 Mar;18(2):92-5. doi: 10.1097/RHU.0b013e31823ecd73.

PMID:
22334272
14.

Tocilizumab may be a potential addition to our weapons against neuro-Behçet's disease.

Borhani Haghighi A, Safari A.

Med Hypotheses. 2008;71(1):156-7. doi: 10.1016/j.mehy.2008.01.011. Epub 2008 Mar 4. No abstract available.

PMID:
18304751
15.

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S34-S40. Epub 2016 Apr 7.

PMID:
27054359
16.

Late response to anti-TNF-α therapy in refractory mucocutaneous lesions of Behçet's disease.

Aikawa NE, Gonçalves C, Silva CA, Gonçalves C, Bonfá E, de Carvalho JF.

Rheumatol Int. 2011 Aug;31(8):1097-9. doi: 10.1007/s00296-009-1276-x. Epub 2009 Dec 11.

PMID:
20012049
17.

Tocilizumab in severe and refractory non-infectious uveitis.

Papo M, Bielefeld P, Vallet H, Seve P, Wechsler B, Cacoub P, Le Hoang P, Papo T, Bodaghi B, Saadoun D.

Clin Exp Rheumatol. 2014 Jul-Aug;32(4 Suppl 84):S75-9. Epub 2014 Sep 30.

PMID:
25268663
18.

Intestinal Behçet's disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis.

Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH.

World J Gastroenterol. 2013 Aug 28;19(32):5389-92. doi: 10.3748/wjg.v19.i32.5389.

19.

Biological treatments in Behçet's disease: beyond anti-TNF therapy.

Caso F, Costa L, Rigante D, Lucherini OM, Caso P, Bascherini V, Frediani B, Cimaz R, Marrani E, Nieves-Martín L, Atteno M, Raffaele CG, Tarantino G, Galeazzi M, Punzi L, Cantarini L.

Mediators Inflamm. 2014;2014:107421. doi: 10.1155/2014/107421. Epub 2014 Jun 30. Review.

20.

Outcome predictors for intestinal Behçet's disease.

Park JJ, Kim WH, Cheon JH.

Yonsei Med J. 2013 Sep;54(5):1084-90. doi: 10.3349/ymj.2013.54.5.1084. Review.

Supplemental Content

Support Center